A new DNA test can analyse proteins in the blood and can help detect 18 different kinds of early-stage cancers across main organs in the human body.
Early detection of cancer can
improve chances of successful treatment and survival. US researchers have come
up with a DNA test that can identify 18 types of early-stage cancers covering
all major human organs accurately, reported The Guardian. Early-stage cancers
are difficult to detect. Lab tests for blood, urine, and other body fluids may
not be a full-proof way to detect cancer and have to be followed with biopsies and
imaging. This multi-screening test for early cancer detection can prove to be a
gamechanger, easing cancer treatment and ensuring higher survival rates among
cancer patients.
The new DNA test can analyse proteins in the blood and
can help detect 18 different kinds of early-stage cancers across main organs in
the human body. Genetic testing, also known as DNA testing, is used to identify
changes in DNA sequence or chromosome structure. While blood proteins have been
used earlier, the accuracy and specificity of the test outperforms previous
ones says the team from the US biotech firm Novelna that has been working on
it.
"This finding is the foundation for a
multi-cancer screening test for the early detection of 18 solid tumours that
cover all major human organs of origin for such cancers at the earliest stage
of their development with high accuracy," the research team told journal
BMJ Oncology.
“This could
re-shape screening guidelines, making this plasma test a standard part of
routine check-ups. These findings pave the way for a cost-effective, highly
accurate, multi-cancer screening test that can be implemented on a
population-wide scale," they added.
The team took blood plasma samples from 440 people
that were diagnosed with 18 different types of cancer and from 44 healthy blood
donors. The researchers could identify the proteins that signalled early-stage
cancers accurately.
“At stage I (the earliest cancer stage) and at the
specificity of 99%, our panels were able to identify 93% of cancers among males
and 84% of cancers among females," they said.
“Our sex-specific localisation panels consisted of 150
proteins and were able to identify the tissue of origin of most cancers in more
than 80% of cases," the researchers added.
The test is significant in a way that it can help
diagnose pre-cancerous and early-stage cancer before a tumour could do
significant damage.
The research team, however, said due to the smaller
size of samples, more studies were needed to establish effectiveness of the
test.
No comments:
Post a Comment